Supplementary Materials
This PDF file includes:
- Materials and Methods
- Fig. S1. HES1 in αSMA+ myofibroblasts and CK7+ cholangiocytes in human livers.
- Fig. S2. NASH diet feeding induces steatohepatitis and fibrosis in WT mice.
- Fig. S3. Characterization of NASH diet–fed L-DNMAM mice.
- Fig. S4. Characterization of NASH diet–fed L-Ncst mice.
- Fig. S5. Characterization of L-DNMAM mice on NASH diet for 32 weeks.
- Fig. S6. Hepatocyte Notch loss of function does not protect from MCD-induced liver fibrosis.
- Fig. S7. Characterization of NASH diet–fed Notch gain-of-function mice.
- Fig. S8. Characterization of chow-fed L-NICD male mice.
- Fig. S9. Characterization of chow-fed L-NICD female mice.
- Fig. S10. Loss of hepatocyte Notch activity does not affect DRs.
- Fig. S11. Hepatocyte Notch activity regulates Spp1 and Sox9 expression.
- Fig. S12. Additional characterization of AAV8-H1-shSpp1–transdudced mice.
- Fig. S13. Characterization of GSI-treated, NASH diet–fed mice.
- Fig. S14. Additional characterization of GSI- and ASO-treated mice.
- Fig. S15. Comparison of saline- and control ASO-treated mice.
- Fig. S16. Model of hepatocyte Notch action to increase NASH-associated fibrosis.
- Table S1. Demographic and clinical features of PIVENS patients.
- Table S2. Demographic and clinical features of patients with suspected NASH.
- Table S3. Sequences of quantitative polymerase chain reaction primers used in the experiments.
- References (69–76)